A meta-analysis of 26 randomized controlled trials involving nearly 49,000 participants found that semaglutide was associated with a 17% reduction in new-onset atrial fibrillation, independent of BMI, age, or glycemic status, with the greatest benefit seen when not combined with SGLT2 inhibitors [25]. The gene discussed is SLC5A2; the disease is atrial fibrillation.